Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. DESIGN, SETTINGS, PARTICIPANTS, & METHODS: The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between 1989 and 1993. We measured ADMA in frozen samples collected at baseline (n = 820) and obtained survival status, up to December 31, 2000, from the National Death Index. We examined the relationship of ADMA with prevalent CVD and performed multivariable Cox models to examine the relationship of ADMA with all-cause and CVD mortality. RESULTS: Mean (SD) age was 52 (12) yr, GFR was 32 +/- 12 ml/min per 1.73 m(2), and ADMA was 0.70 +/- 0.25 micromol/L. A 1-SD increase in ADMA was associated with a 31% increased odds of prevalent CVD in an adjusted logistic regression model. During the 10-yr follow-up period, 202 (25%) participants died of any cause, 122 (15%) from CVD, and 545 (66%) reached kidney failure. In multivariable Cox models, a 1-SD increase in ADMA was associated with a 9% increased risk for all-cause and 19% increased risk for CVD mortality. CONCLUSIONS: In this cohort of patients with predominantly nondiabetic, stages 3 to 4 chronic kidney disease, there was a strong association of ADMA with prevalent CVD and a modest association with all-cause and CVD mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Self-citationBöger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine
Valkonen, V.-P., Päivä, H., Salonen, J. T., Lakka, T. A., Lehtimäki, T., Laakso, J., & Laaksonen, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07184-7 · Cited by 562 · cited 1×
“High ADMA levels were an index of carotid intima-media thickness and were associated with future acute coronary events in general population studies (10,11).”
BackgroundClinical subtypes of Alzheimer’s disease
Petersen, R. C. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051199 · Cited by 223
Cited by
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
The role of asymmetric and symmetric dimethylarginines in renal disease
Schwedhelm, E., & Böger, R. H. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.31 · Cited by 260
Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms
Kaur, J., Young, B., & Fadel, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081682 · Cited by 168
Chen, J., Hamm, L. L., Bundy, J. D., Kumbala, D. R., Bodana, S., Chandra, S., Chen, C.-S., Starcke, C. C., Guo, Y., Schaefer, C. M., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02020220 · Cited by 16
Ventricular arrhythmias in mouse models of diabetic kidney disease
Laurita, K. R., Khan, S., McMahon, T., Dennis, A. T., Li, V., Gaivin, R., Sapa, H., Fu, J.-D., & Schelling, J. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-99891-9 · Cited by 8
Metadata
- Authors
- Young, J. M., Terrin, N., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Sarnak, M. J., & Menon, V.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-06
- Volume
- 4
- Issue
- 6
- Pages
- 1115-1120
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2048121996
- Cited by
- 96
- References
- 4
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease. https://app.cochat.ai/papers/10.2215/cjn.06671208
- The paper
- Young, J. M., Terrin, N., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Sarnak, M. J., & Menon, V. (2009). Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.06671208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.